SCYNEXIS to Participate in Upcoming January 2022 Investor Conferences

January 6, 2022 |

1 min read

SCYNEXIS, Inc. announced that Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will present during two virtual investor conferences in January.

JERSEY CITY, N.J., Jan. 06, 2022 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced that Marco Taglietti, M.D., President and Chief Executive Officer of SCYNEXIS, will present during two virtual investor conferences in January.

Presentation details:

LifeSci Partners 11^th Annual Corporate Access Event
Format: Virtual panel discussion with CEO and 1:1 meetings
Panel Title: The Best of Both Worlds – Defining Yourself When You Fit into More Than One Basket
Date and Time: Friday, January 7, at 10:00 a.m. ET
Registration link:LifeSci Partners Corporate Access Event 2022

H.C. Wainwright Bioconnect 2022 Virtual Healthcare Conference
Format: Virtual event with webcast of corporate update presentation by Dr. Taglietti
Date and Time: Presentation webcast will be available on-demand January 10-13 for event participants
Registration link:H.C. Wainwright Bioconnect 2022

The latest SCYNEXIS investor presentation can be found on the corporate website here.

About SCYNEXIS

SCYNEXIS, Inc. (NASDAQ: SCYX) is a biotechnology company pioneering innovative medicines to help millions of patients worldwide overcome and prevent difficult-to-treat infections that are becoming increasingly drug-resistant. We are developing our lead asset, ibrexafungerp (formerly known as SCY-078), as a broad-spectrum, systemic antifungal for multiple fungal indications in both the community and hospital settings. The New Drug Application (NDA) for BREXAFEMME^® (ibrexafungerp tablets) was approved by the U.S. Food and Drug Administration (FDA) on June 1, 2021. For more information, visit www.brexafemme.com. We are also continuing late-stage clinical development of ibrexafungerp for the prevention of recurrent VVC as well as the treatment of life-threatening invasive fungal infections in hospitalized patients. For more information, visit www.scynexis.com.

CONTACT:
Investor Relations
Irina Koffler
LifeSci Advisors
Tel: (646) 970-4681
ikoffler@lifesciadvisors.com

Media Relations
Gloria Gasaatura
LifeSci Communications
Tel: (646) 970-4688
ggasaatura@lifescicomms.com

Events